Evidence map›Paper›PMID 37462076›Full record

ArticleNucleic acids research2023

Ncs2* mediates in vivo virulence of pathogenic yeast through sulphur modification of cytoplasmic transfer RNA.

Fiona Alings, Karin Scharmann, Cristian Eggers, Bettina Böttcher, Mikołaj Sokołowski, Ekaterina Shvetsova, Puneet Sharma, Joël Roth, Leon Rashiti, Sebastian Glatt and 2 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. RNA modification is the mark and strategy for host-microbe interactions.Cellular and molecular life sciences : CMLS · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Fiona AlingsMax Planck Research Group for RNA Biology, Max Planck Institute for Molecular Biomedicine, Muenster, Germany.
Karin ScharmannMax Planck Research Group for RNA Biology, Max Planck Institute for Molecular Biomedicine, Muenster, Germany.
Cristian EggersMax Planck Research Group for RNA Biology, Max Planck Institute for Molecular Biomedicine, Muenster, Germany.
Bettina BöttcherDepartment of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knoell Institute, Jena, Germany.
Mikołaj SokołowskiMax Planck Research Group at the Malopolska Centre of Biotechnology, Jagiellonian University, Krakow, Poland.
Ekaterina ShvetsovaDepartment of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, Switzerland.
Puneet SharmaMax Planck Research Group for RNA Biology, Max Planck Institute for Molecular Biomedicine, Muenster, Germany.
Joël RothDepartment of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, Switzerland.
Leon RashitiDepartment of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, Switzerland.
Sebastian GlattMax Planck Research Group at the Malopolska Centre of Biotechnology, Jagiellonian University, Krakow, Poland.ORCID 0000-0003-2815-7133
Sascha BrunkeDepartment of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knoell Institute, Jena, Germany.ORCID 0000-0001-7740-4570
Sebastian A LeidelMax Planck Research Group for RNA Biology, Max Planck Institute for Molecular Biomedicine, Muenster, Germany.ORCID 0000-0002-0523-6325
University of Bern · CHJagiellonian University · PLLeibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI) · DEMax Planck Institute for Molecular Biomedicine · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fungal pathogens threaten ecosystems and human health. Understanding the molecular basis of their virulence is key to develop new treatment strategies. Here, we characterize NCS2*, a point mutation identified in a clinical baker's yeast isolate. Ncs2 is essential for 2-thiolation of tRNA and the NCS2* mutation leads to increased thiolation at body temperature. NCS2* yeast exhibits enhanced fitness when grown at elevated temperatures or when exposed to oxidative stress, inhibition of nutrient signalling, and cell-wall stress. Importantly, Ncs2* alters the interaction and stability of the thiolase complex likely mediated by nucleotide binding. The absence of 2-thiolation abrogates the in vivo virulence of pathogenic baker's yeast in infected mice. Finally, hypomodification triggers changes in colony morphology and hyphae formation in the common commensal pathogen Candida albicans resulting in decreased virulence in a human cell culture model. These findings demonstrate that 2-thiolation of tRNA acts as a key mediator of fungal virulence and reveal new mechanistic insights into the function of the highly conserved tRNA-thiolase complex.

Indexed as

RNA, TransferSaccharomyces cerevisiaeAnimalsCandida albicansCell Cycle ProteinsEcosystemFungal ProteinsHumansMiceSaccharomyces cerevisiae ProteinsSulfurVirulenceCell Cycle ProteinsFungal ProteinsNCS2 protein, S cerevisiaeRNA, TransferSaccharomyces cerevisiae ProteinsSulfur

Identifiers

PMID37462076
PMCPMC10450187
OpenAlexW4384626281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.